GLSI — Greenwich Lifesciences Share Price
0.000.00%
Last trade - 00:00- $118.80m
- $112.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 23.84 | ||
| Price to Tang. Book | 23.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -216.01% | ||
| Return on Equity | -151.72% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.
Directors
- David McWilliams NEC (78)
- Snehal Patel CEO (57)
- Jaye Thompson VPR (55)
- F. Joseph Daugherty OTH (70)
- Kenneth Hallock IND (72)
- Eric Rothe IND (46)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- August 29th, 2006
- Public Since
- September 25th, 2020
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 13,273,539
- Address
- 3992 Bluebonnet Dr, Building 14, STAFFORD, 77477
- Web
- https://greenwichlifesciences.com
- Phone
- +1 2034343290
- Auditors
- Malone Bailey, LLP
Upcoming Events for GLSI
Q2 2025 Greenwich Lifesciences Inc Earnings Release
Similar to GLSI
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Greenwich Lifesciences share price?
As of Today at 20:56 UTC, shares in Greenwich Lifesciences are trading at $8.95. This share price information is delayed by 15 minutes.
How has the Greenwich Lifesciences share price performed this year?
Shares in Greenwich Lifesciences last closed at $8.95 and the price had moved by -31.42% over the past 365 days. In terms of relative price strength the Greenwich Lifesciences share price has underperformed the S&P500 Index by -35.51% over the past year.
What are the analyst and broker recommendations for Greenwich Lifesciences?
The overall consensus recommendation for Greenwich Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Greenwich Lifesciences dividend yield?
Greenwich Lifesciences does not currently pay a dividend.
Does Greenwich Lifesciences pay a dividend?
Greenwich Lifesciences does not currently pay a dividend.
When does Greenwich Lifesciences next pay dividends?
Greenwich Lifesciences does not currently pay a dividend.
How do I buy Greenwich Lifesciences shares?
To buy shares in Greenwich Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Greenwich Lifesciences?
As of the previous close price of $8.95, shares in Greenwich Lifesciences had a market capitalisation of $118.80m.
Where are Greenwich Lifesciences shares listed?
Here are the trading details for Greenwich Lifesciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: GLSI
What kind of share is Greenwich Lifesciences?
Based on an overall assessment of its quality, value and momentum Greenwich Lifesciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Greenwich Lifesciences share price forecast for 2025?
The analyst consensus target price for shares in Greenwich Lifesciences is $38.00. That is 324.58% above the last closing price of $8.95.
Analysts covering Greenwich Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.80 for the next financial year.
Find out moreWhat is the trend in the Greenwich Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Greenwich Lifesciences. Over the past six months, its share price has underperformed the S&P500 Index by -26.7%.
As of the last closing price of $8.95, shares in Greenwich Lifesciences were trading -32.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Greenwich Lifesciences PE Ratio?
The Greenwich Lifesciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Greenwich Lifesciences?
Greenwich Lifesciences' management team is headed by:
- David McWilliams - NEC
- Snehal Patel - CEO
- Jaye Thompson - VPR
- F. Joseph Daugherty - OTH
- Kenneth Hallock - IND
- Eric Rothe - IND